

St. John Fisher University

Fisher Digital Publications

Pharmacy Faculty/Staff Publications

Wegmans School of Pharmacy

1-2010

Resolution of Clinical Signs in Trauma Intensive Care Unit Patients Following Diagnosis of Ventilator-Associated Pneumonia

Kathryn A. Connor

St. John Fisher University, kaconnor@sjf.edu

Joseph M. Swanson

G. Christopher Wood

Bradley A. Boucher

Louis J. Magnotti

University of Tennessee Health Services Center

Follow this and additional works at: https://fisherpub.sjf.edu/pharmacy_facpub



Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

[How has open access to Fisher Digital Publications benefited you?](#)

Publication Information

Connor, Kathryn A.; Swanson, Joseph M.; Wood, G. Christopher; Boucher, Bradley A.; and Magnotti, Louis J., "Resolution of Clinical Signs in Trauma Intensive Care Unit Patients Following Diagnosis of Ventilator-Associated Pneumonia" (2010). *Pharmacy Faculty/Staff Publications*. Paper 36.

https://fisherpub.sjf.edu/pharmacy_facpub/36

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit <http://libguides.sjfc.edu/citations>.

This document is posted at https://fisherpub.sjf.edu/pharmacy_facpub/36 and is brought to you for free and open access by Fisher Digital Publications at . For more information, please contact fisherpub@sjf.edu.

Resolution of Clinical Signs in Trauma Intensive Care Unit Patients Following Diagnosis of Ventilator-Associated Pneumonia

Abstract

PURPOSE: The ATS/IDSA Ventilator-Associated Pneumonia (VAP) guidelines suggest that clinical improvement of VAP should be apparent within 3-6 days. Anecdotally, such improvement has not been noted in trauma patients at our institution. The current study was conducted to evaluate resolution of clinical signs of VAP following diagnosis.

METHODS: Critically injured adults admitted to the trauma intensive care unit (TICU) from 6/1/06-12/31/07 and subsequently diagnosed with VAP were retrospectively reviewed. Clinical signs, including derangements of maximum temperature (Tmax), white blood cell (WBC) count and PaO₂/FiO₂, were evaluated on days 1-16 following VAP diagnosis. Data are presented as mean ± SD unless otherwise stated. Clinical parameters following VAP were compared using repeated measures ANOVA with the Tukey test for multiple comparisons.

RESULTS: A total of 82 patients were identified. Data for the 34 patients without concurrent infections are presented. Demographic data include: Age 46 ± 17 years; 71% males; 94% blunt trauma; median (IQR) Injury Severity Score 29.5 (24 to 38); duration of mechanical ventilation 33 ± 27 days; ICU length of stay (LOS) 39 ± 25 days; hospital LOS 53 ± 33 days. Clinical signs following VAP diagnosis (Figure): Tmax (°F): Day 1=101.8 ± 1.3, Day 3=101.1 ± 1.1, Day 6=101.1 ± 1.4, Day 16=100.1 ± 3. Compared to Day 1, there was a significant reduction in Tmax at Days 10, 11, 12, 13, 14 and 16 (p < 0.05 for all). WBC count (cells/μL): Day 1=12.9 ± 5, Day 3=13.7 ± 5, Day 6=14.4 ± 5, Day 16=13.8 ± 6. There was no significant difference in WBC count on Days 1-16 (p=0.42). PaO₂/FiO₂: Day 1=232 ± 108, Day 3=200 ± 87, Day 6=218 ± 104, Day 16=246 ± 126. Differences in PaO₂/FiO₂ on Days 1-16 did not reach statistical significance (p=0.06).

CONCLUSIONS: In trauma patients, improvement of clinical parameters following diagnosis of VAP is delayed beyond the 3-6 day timeframe suggested in the ATS/IDSA guidelines. Alternative methods for determining resolution of VAP in trauma patients should be investigated. METHODS INTRODUCTION

Disciplines

Pharmacy and Pharmaceutical Sciences

Comments

This was presented at the Society of Critical Care Medicine's 39th Critical Care Congress, Miami Beach, Florida, January 2010.



Resolution of Clinical Signs in Trauma Intensive Care Unit Patients Following Diagnosis of Ventilator-Associated Pneumonia, ID #311



Kathryn A. Connor, Pharm.D.,¹ Joseph M. Swanson, Pharm. D.¹, G. Christopher Wood, Pharm.D.¹,
Bradley A. Boucher, Pharm.D.¹, Louis J. Magnotti, M.D.²; Dept. of Clinical Pharmacy¹, Dept. of Surgery²
University of Tennessee Health Science Center; 910 Madison Ave.; Memphis, Tennessee 38163

ABSTRACT

PURPOSE: The ATS/IDSA Ventilator-Associated Pneumonia (VAP) guidelines suggest that clinical improvement of VAP should be apparent within 3-6 days. Anecdotally, such improvement has not been noted in trauma patients at our institution. The current study was conducted to evaluate resolution of clinical signs of VAP following diagnosis.

METHODS: Critically injured adults admitted to the trauma intensive care unit (TICU) from 6/1/06-12/31/07 and subsequently diagnosed with VAP were retrospectively reviewed. Clinical signs, including derangements of maximum temperature (Tmax), white blood cell (WBC) count and PaO₂/FiO₂, were evaluated on days 1-16 following VAP diagnosis. Data are presented as mean ± SD unless otherwise stated. Clinical parameters following VAP were compared using repeated measures ANOVA with the Tukey test for multiple comparisons.

RESULTS: A total of 82 patients were identified. Data for the 34 patients without concurrent infections are presented. Demographic data include: Age 46 ± 17 years; 71% males; 94% blunt trauma; median (IQR) Injury Severity Score 29.5 (24 to 38); duration of mechanical ventilation 33 ± 27 days; ICU length of stay (LOS) 39 ± 25 days; hospital LOS 53 ± 33 days. Clinical signs following VAP diagnosis (Figure): Tmax (°F): Day 1=101.8 ± 1.3, Day 3=101.1 ± 1.1, Day 6=101.1 ± 1.4, Day 16=100.1 ± 3. Compared to Day 1, there was a significant reduction in Tmax at Days 10, 11, 12, 13, 14 and 16 (p < 0.05 for all). WBC count (cells/μL): Day 1=12.9 ± 5, Day 3=13.7 ± 5, Day 6=14.4 ± 5, Day 16=13.8 ± 6. There was no significant difference in WBC count on Days 1-16 (p=0.42). PaO₂/FiO₂: Day 1=232 ± 108, Day 3=200 ± 87, Day 6=218 ± 104, Day 16=246 ± 126. Differences in PaO₂/FiO₂ on Days 1-16 did not reach statistical significance (p=0.06).

CONCLUSIONS: In trauma patients, improvement of clinical parameters following diagnosis of VAP is delayed beyond the 3-6 day timeframe suggested in the ATS/IDSA guidelines. Alternative methods for determining resolution of VAP in trauma patients should be investigated.

INTRODUCTION

VAP is the most frequent ICU-acquired infection among mechanically ventilated patients, associated with increased morbidity, costs and ~30-70% mortality. The VAP Guidelines use clinical parameters to define normal pattern of resolution, i.e., WBC (normal: 5-10 cells/μL), temperature (normal: 98.6° F), PaO₂:FiO₂ (normal : 380 -475)¹. These guidelines suggest clinical improvement is seen at ≥ 72 hours, and recommend a duration of therapy of 7-14 days. Denneson *et al* described resolution of VAP in a mixed ICU and noted trends of WBC, temperature and PaO₂:FiO₂ over time². He found that response occurred in 6 days, which is different than the guidelines. However, trauma patients are different, as they have a 2-3x greater incidence of VAP than other populations³, and 90% experience systemic inflammatory response syndrome (SIRS) in the 1st week⁴.

PURPOSE

We were interested in determining if Denneson's findings could be extrapolated to ventilated patients in other settings. Our purpose was to describe resolution of clinical signs of VAP in trauma patients. We hypothesized that trauma patients have delayed resolution of clinical signs of VAP.

METHODS

Design: Retrospective review from pre-existing database

Inclusion Criteria: Critically injured trauma patients diagnosed with VAP

Exclusion Criteria: Age <18 years, pregnant, immunocompromised, immunosuppressed

Clinical Endpoints: Improvement or resolution of temperature, WBC, PaO₂: FiO₂


Statistical analysis: Descriptive Statistics, one-way repeated measures ANOVA for daily comparisons of clinical parameters

All patients diagnosed with fiberoptic bronchoscopy, treated with current TICU VAP Pathway

RESULTS


	All Patients (n = 82)	Patients without Concurrent Infections (n = 34)	Patients with Concurrent Infections (n = 48)	P value
Age	44 ± 17	46 ± 17	43 ± 17	0.39
Males/Females (% Male)	60/23 (72)	24/10 (71)	36/13 (73)	0.97
MOI, (% Blunt)	86	32/2 (94)	39/10 (80)	0.11
Injury Severity Score, median (IQR)	34 (25 to 42)	29.5 (24 to 38)	34 (26 to 42)	0.19
MV	32 ± 32	33 ± 27	32 ± 36	0.49
ICU LOS	37 ± 31	39 ± 25	36 ± 34	0.21
Hospital LOS	51 ± 38	53 ± 33	49 ± 42	0.11
Mortality, Dead/Alive (%)	16/67 (19)	4/30 (12)	12/37 (25)	0.25

WBC Count Over Time




RESULTS - CONTINUED

Maximum Temperature Over Time



PaO₂/FiO₂ Over Time



CONCLUSIONS

Rapid resolution of signs of VAP is not seen in trauma patients as suggested by the VAP guidelines, and similar to the results of Denneson's study. Clinical parameter trends show a slow response to appropriate antimicrobial therapy. Future studies should explore other methods to determine clinical response to VAP in trauma patients, in order to avoid unnecessary antibiotic use and adverse effects and minimize costs.

References: 1. *Am J Respir Crit Care Med*, 2005; 388-416. 2. *A Am J Respir Crit Care Med*. 2001;163:1375. 3. *Am J Infect Cont*. 2008; 36(9):609-626. 4. *J Trauma*. 2006;61:310 -317.